Emergent BioSolutions | EBS - ايرادات المبيعات





مبيعات تغيير تاريخ
Acadia Pharmaceuticals USD 284M 5.4M 2025-12
Akebia Therapeutics USD 57.62M 1.14M 2025-12
ALKERMES USD 384.5M 9.7M 2025-12
Alnylam Pharmaceuticals USD 1.1B 150M 2025-12
Amarin USD 49.22M 451K 2025-12
ANI Pharmaceuticals USD 247.06M 19.25M 2025-12
BioMarin Pharmaceutical USD 875M 99M 2025-12
Coherus Biosciences USD 12.75M 1.18M 2025-12
Emergent BioSolutions USD 276.6M 6.1M 2023-12
Exelixis USD 598.66M 860K 2025-12
Glaxosmithkline GBP 11.46B 59.16M 2025-12
Heron Therapeutics USD 40.59M 2.38M 2025-12
Ionis Pharmaceuticals USD 203M 46M 2025-12
Ironwood Pharmaceuticals USD 47.71M 74.35M 2025-12
Lexicon Pharmaceuticals USD 5.49M 8.69M 2025-12
Lonza CHF 3.58B 63M 2025-06
Merck USD 16.4B 880M 2025-12
Moderna USD 678M 342M 2025-12
Myriad Genetics USD 209.8M 4.1M 2025-12
Nektar Therapeutics USD 21.81M 2.32M 2025-12
Neurocrine Biosciences USD 805.5M 10.6M 2025-12
Pacira USD 196.87M 17.35M 2025-12
Pfizer USD 17.58B 880M 2025-12
PTC Therapeutics USD 164.7M 46.3M 2025-12
Sanofi EUR 11.24B 60M 2026-03
Sarepta Therapeutics USD 442.9M 43.5M 2025-12
United Therapeutics USD 790.2M 9.3M 2025-12
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12
Xoma USD 25K 5M 2024-09